Merck & Co., Inc.
Close on Oct 30, 2026Market cap $368.89BP/E 119.6Yield 2.19%
Merck ProQuad / M-M-R II / Varivax by Year
ProQuad / M-M-R II / Varivax (Combined Pediatric Vaccines Franchise) — Worldwide reported growth YoY (%) (%)
Merck ProQuad / M-M-R II / Varivax: -1.0% in FY2025, down 6.0 pts from a year earlier.
Where the FY2025 figure comes from
“|| ProQuad/M-M-R II/Varivax | 2,451 | 2,485 | -1 | 1,885 | 1,919 | -2 | 566 | 566 | 0”
Source: Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗
Reported in Form 8-K Table 3 / 3a / 3b Product Sales.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | ProQuad / M-M-R II / Varivax (Combined Pediatric Vaccines Franchise) — Worldwide reported growth YoY (%) (%) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | -1.0% | -6.0 pts | Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗ |
| FY2024 | Dec 31, 2024 | 5.0% | – | Form 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗ |
Cite this data
StockData. (2026). Merck ProQuad / M-M-R II / Varivax (%), annual FY2024–FY2025 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev-proquad-mmr-varivax-ww-nom-yoy
See every metric in the Merck KPI table. Data updated Oct 26, 2026.